UBS Group AG Acquires 184,453 Shares of Oruka Therapeutics, Inc. $ORKA

UBS Group AG lifted its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 213.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 271,013 shares of the company’s stock after purchasing an additional 184,453 shares during the quarter. UBS Group AG’s holdings in Oruka Therapeutics were worth $8,214,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ORKA. Goldman Sachs Group Inc. bought a new position in shares of Oruka Therapeutics during the 1st quarter worth about $2,505,000. JPMorgan Chase & Co. lifted its holdings in shares of Oruka Therapeutics by 567.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock worth $173,000 after acquiring an additional 13,115 shares during the period. Legal & General Group Plc bought a new position in shares of Oruka Therapeutics during the 2nd quarter worth about $28,000. Rhumbline Advisers bought a new position in shares of Oruka Therapeutics during the 2nd quarter worth about $320,000. Finally, New York State Common Retirement Fund bought a new position in shares of Oruka Therapeutics during the 2nd quarter worth about $96,000. 56.44% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $61.85, for a total transaction of $432,950.00. Following the completion of the sale, the insider owned 33,377 shares in the company, valued at $2,064,367.45. The trade was a 17.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 30,765 shares of company stock valued at $1,522,695 in the last 90 days. Corporate insiders own 23.49% of the company’s stock.

Oruka Therapeutics Stock Performance

ORKA opened at $61.93 on Monday. The stock has a market capitalization of $3.73 billion, a PE ratio of -31.92 and a beta of -0.20. Oruka Therapeutics, Inc. has a 1-year low of $9.40 and a 1-year high of $91.00. The firm has a 50-day moving average price of $55.17 and a two-hundred day moving average price of $39.42.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, research analysts predict that Oruka Therapeutics, Inc. will post -2.15 EPS for the current year.

Analyst Upgrades and Downgrades

ORKA has been the subject of a number of analyst reports. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a report on Monday, April 27th. BTIG Research reaffirmed a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Thursday. Stifel Nicolaus lifted their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Leerink Partners set a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday, April 30th. Finally, UBS Group lifted their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Oruka Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $120.80.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.